Screening rare genetic diagnoses for amenability to bespoke antisense oligonucleotide therapy development: a retrospective cohort study
Cheerie, D.; Lauffer, M. C.; Newton, L.; Amburgey, K.; Beijer, D.; Haque, B.; Kalish, B. T.; Meserve, M.; Oh, R. Y.; Pan, A. Y.; Reuter, M.; Szego, M. J.; Szuto, A.; N=1 Collaborative, ; Aartsma-Rus, A.; Axford, M. M.; Deshwar, A. R.; Dowling, J. J.; Marshall, C. R.; Ivakine, Z.; Synofzik, M.; Yu, T. W.; Costain, G.
Show abstract
PurposeTo estimate the proportion of molecular genetic diagnoses in a real-world, phenotypically heterogeneous patient cohort that are amenable to antisense oligonucleotide (ASO) treatment. MethodsWe retrospectively applied the N=1 Collaboratives VARIANT (Variant Assessments towards Eligibility for Antisense Oligonucleotide Treatment) guidelines to all diagnostic variants found by clinical genome-wide sequencing at a single pediatric hospital in 532 patients over a 6-year period. Variants were classified as either "eligible", "likely eligible", "unlikely eligible", or "not eligible" in relation to the different ASO approaches, or "unable to assess". ResultsIn total, 25 unique variants across 26 patients (4.9% of 532 patients) were eligible or likely eligible for ASO treatment at a molecular genetic level, via canonical exon skipping (4), splice correction (3), or mRNA knockdown (18). Only eight of these molecular genetic diagnoses were made within a year of symptom onset. After considering disease and delivery related factors, 11 diagnoses were still considered candidates for bespoke ASO development. ConclusionA meaningful proportion of genetic diagnoses identified by genome-wide sequencing may be amenable to ASO treatment. These results underscore the importance of timely diagnosis, and the proactive identification and accelerated functional testing of genetic variants amenable to ASO treatments.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Evaluation of Bayesian Classification Framework on the Variant Classification of Hereditary Cancer Predisposition Genes 94%
- Variant Curation Expert Panel Recommendations for RYR1 Pathogenicity Assertions in Malignant Hyperthermia Susceptibility 94%
- Utility of genome sequencing and group-enrichment to support splice variant interpretation in Marfan syndrome 94%
Similar papers in this journal
- Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments 97%
- Advanced variant classification framework reduces the false positive rate of predicted loss of function (pLoF) variants in population sequencing data 94%
- Exome copy number variant detection, analysis and classification in a large cohort of families with undiagnosed rare genetic disease 93%
Similar papers in this journal
Similar papers in this journal
- Combined Bioinformatic and Splicing Analysis of Likely Benign Intronic and Synonymous Variants Reveals Evidence for Pathogenicity 92%
- Genetic Diagnosis of Facioscapulohumeral Muscular Dystrophy Type 1 Using Rare Variant Linkage Analysis and Long Read Genome Sequencing 90%
- 3-hour genome sequencing and targeted analysis to rapidly assess genetic risk 90%
Similar papers in this journal
- Comprehensive reanalysis for CNVs in ES data from unsolved rare disease cases results in new diagnoses 91%
- Pathogenic Neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq 91%
- Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.